International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Posted · Add Comment

The updated criteria for the diagnosis of myeloma represent a paradigm shift in the approach to myeloma and have considerable impact on the management of the disease. For decades the diagnosis of multiple myeloma required the presence of end-organ damage known as the CRAB criteria, including increased calcium level, renal dysfunction, anemia, and destructive bone lesions. The updated criteria allow for treatment of patients who are at such high risk of progression to symptomatic disease that it is clear they would benefit from therapy and also potentially live longer if they were treated before serious organ damage occurred. The revised IMWG criteria allow, in addition to the classic CRAB features, […]

International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma

Posted · Add Comment

The International Myeloma Working Group established the below criteria in order to: facilitate precise comparisons of efficacy between new treatment strategies in trials incorporate the serum free light chain (FLC) assay to include assessment of patients with oligo-secretory and non-secretory disease provide stricter definitions for CR (complete response) provide classifications that would improve detail and correct inconsistencies in prior response criteria. The following criteria reconcile various previously used systems for assessing response and have been universally adopted. Response IMWG criteria sCR CR as defined below plus normal FLC ratio and absence of clonal cells in bone marrow3 by immunohistochemistry or immunofluorescence4 CR Negative immunofixation on the serum and urine and […]

International uniform response criteria for multiple myeloma

Posted · Add Comment

New uniform response  criteria are required to adequately assess clinical outcomes in myeloma. The European Group for Blood and Bone Marrow Transplant/International Bone Marrow Transplant Registry criteria have been expanded, clari?ed and updated to provide a new comprehensive evalua- tion system. Categories for stringent complete response and very good partial response are added. The serum free light- chain assay is included to allow evaluation of patients with oligo-secretory disease. Inconsistencies in prior criteria are clari?ed making con?rmation of response and disease progres- sion easier to perform. Emphasis is placed upon time to event and duration of response as critical end points. The require- ments necessary to use overall survival duration […]